Dostinex 0.5 mg contains cabergoline, a long-acting dopamine agonist. It works mainly by stimulating dopamine receptors and reducing the production and release of the hormone prolactin. It is commonly prescribed for conditions associated with abnormally high prolactin levels, including hyperprolactinemia and prolactin-producing pituitary tumors (prolactinomas).

Specifications

• Brand: Dostinex
• Active ingredient: Cabergoline
• Strength: 0.5 mg (500 micrograms) per tablet
• Pack size: 8 tablets
• Dosage form: Tablet
• Drug class: Dopamine agonist / prolactin inhibitor
• Route: Oral
• Prescription: Prescription medicine
• Main action: Reduces elevated prolactin levels

Medical Uses

Cabergoline is used to treat hyperprolactinemia, where the body produces too much prolactin. It may be prescribed for prolactinomas and other conditions associated with elevated prolactin. Lowering prolactin can help restore menstrual cycles and ovulation in some women and improve fertility when high prolactin is contributing to these problems.

Some cabergoline products are also licensed for suppression or prevention of physiological lactation; however, the approved uses and recommendations can vary by country and product.

Benefits

• Helps lower abnormally high prolactin levels.
• Can help control symptoms caused by hyperprolactinemia.
• May help restore normal menstrual cycles and ovulation when elevated prolactin is the cause.
• May improve fertility associated with high prolactin.
• In patients with prolactinoma, treatment can reduce prolactin production and may reduce tumor size.

How to Use

Take Dostinex exactly as prescribed by your doctor. Cabergoline is long-acting and is commonly taken once or twice weekly rather than every day. The dose is usually started low and gradually adjusted according to prolactin levels and response to treatment.

Taking it with or after food may help reduce nausea. Do not take extra tablets if you miss a dose; follow your doctor's or pharmacist's instructions.

Laronib 100 mg contains larotrectinib, a targeted anticancer medicine known as a TRK inhibitor. Larotrectinib works by blocking proteins produced from NTRK gene fusions, which can drive the growth and spread of certain solid tumors. It is used in adults and children whose tumors have an NTRK gene fusion, particularly when the cancer is metastatic, surgery would cause severe morbidity, and there is no satisfactory alternative treatment or the disease has progressed after treatment. Tumor testing is used to identify suitable patients.

Specifications

• Brand: Laronib
• Active ingredient: Larotrectinib
• Strength: 100 mg
• Dosage form: Hard capsule
• Drug class: TRK (tropomyosin receptor kinase) inhibitor
• Route: Oral
• Main indication: NTRK gene fusion-positive solid tumors
• Prescription: Specialist prescription medicine
• Administration: With or without food
• Important: Treatment should be initiated and monitored by an oncology specialist.

Medical Uses

Larotrectinib is used for certain NTRK fusion-positive solid tumors. Unlike many traditional cancer medicines that are selected primarily according to where a tumor originated, larotrectinib is selected according to the presence of an NTRK gene fusion. It may be used in adults and pediatric patients when the cancer has spread to other parts of the body, when surgery would be expected to cause severe morbidity, and when satisfactory alternative treatments are unavailable or the cancer has progressed following treatment.

Benefits

• Provides targeted treatment for cancers driven by NTRK gene fusions.
• May inhibit signaling involved in tumor-cell growth.
• Can be used across different types of solid tumors when the required molecular alteration is present.
• Offers an oral treatment option for eligible adult and pediatric patients.
• Treatment selection is based on molecular testing rather than tumor location alone.

How to Use

The recommended dose for adults and pediatric patients with a body surface area of 1 m² or greater is 100 mg twice daily, with or without food. Pediatric patients with a body surface area below 1 m² receive a weight/body-surface-area-based dose determined by their oncologist. Treatment generally continues until disease progression or unacceptable toxicity.

Swallow the capsule whole with water; do not chew or crush it. If a dose is missed and the next scheduled dose is within 6 hours, follow the prescribing instructions rather than taking an extra dose. If vomiting occurs after a dose, the next dose should be taken at the normal scheduled time.

Clobazam 10 mg Tablet contains clobazam, a benzodiazepine medicine that has a calming effect on the brain. It is available as a prescription medicine and may be used for certain seizure disorders and, in some countries, short-term treatment of severe anxiety. Clobazam can cause drowsiness and may lead to tolerance, dependence, and withdrawal if used regularly, so it should be taken only under medical supervision.

Specifications

• Active ingredient: Clobazam
• Strength: 10 mg
• Dosage form: Tablet
• Drug class: Benzodiazepine
• Route: Oral
• Prescription: Prescription medicine
• Main action: Calming and anticonvulsant effects
• Important: Do not stop suddenly after regular use.

Medical Uses

Clobazam may be prescribed as an add-on treatment for certain types of epilepsy, including seizures associated with Lennox-Gastaut syndrome. Depending on the country and product labeling, it may also be prescribed for short-term relief of severe anxiety. Its use for anxiety should be limited and medically supervised.

Benefits

• Helps reduce certain seizure activity when used with other epilepsy medicines.
• Provides a calming effect on the central nervous system.
• May help control symptoms of severe anxiety when specifically prescribed.
• Can be useful as part of a doctor-supervised treatment plan for selected seizure disorders.

How to Use

Take Clobazam 10 mg exactly as prescribed by your doctor, preferably at the same time each day. Swallow the tablet with water, with or without food. The appropriate dose depends on the condition, age, weight, other medicines, and individual response. Do not increase the dose yourself.

Clobazam can cause sleepiness, dizziness, reduced alertness, headache, nausea, constipation, or problems with coordination. Avoid alcohol and be careful with driving or operating machinery until you know how the medicine affects you.

Vyas 30Mg Capsules contain lisdexamfetamine dimesylate 30 mg, a central nervous system (CNS) stimulant used under medical supervision. Lisdexamfetamine is a prodrug that is converted in the body to dextroamphetamine and affects neurotransmitters involved in attention and impulse control. It is primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD) and, in adults, may also be prescribed for moderate-to-severe binge-eating disorder (BED), depending on the approved indication in the relevant country.

Specifications

• Brand: Vyas
• Strength: 30 mg
• Active Ingredient: Lisdexamfetamine dimesylate
• Dosage Form: Hard capsule
• Route: Oral
• Medicine Type: CNS stimulant
• Common Medical Use: ADHD
• Other approved use: Moderate-to-severe BED in adults, where authorized
• Typical Starting Dose: 30 mg once daily for ADHD, according to prescribing information
• Prescription Status: Prescription medicine; controlled-drug restrictions may apply depending on jurisdiction.

Benefits

When appropriately prescribed, Vyas 30Mg may help manage symptoms associated with ADHD, including difficulty maintaining attention, impulsive behavior, and excessive activity. By increasing the activity of certain neurotransmitters such as dopamine and norepinephrine, lisdexamfetamine can support improved attention and behavioral control.

For adults with moderate-to-severe binge-eating disorder, lisdexamfetamine may be prescribed to reduce the frequency of binge-eating episodes. It is not approved as a weight-loss medicine, and it should not be used for weight reduction without appropriate medical advice.

How to Use

Take Vyas 30Mg exactly as prescribed by your doctor. For ADHD, prescribing information recommends once-daily morning administration. The capsule may generally be taken with or without food and should not be divided into multiple doses. Swallow it with water unless your healthcare professional gives different instructions.

Vyas 70mg Capsule contains lisdexamfetamine, a central nervous system stimulant. It is a prescription medicine used primarily for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is a prodrug that is converted in the body to dextroamphetamine, which affects neurotransmitters involved in attention and impulse control. Vyas 70mg is listed as a 70mg lisdexamfetamine capsule.

Specifications

• Brand: Vyas
• Active ingredient: Lisdexamfetamine
• Strength: 70mg
• Dosage form: Capsule
• Drug class: Central nervous system stimulant
• Route: Oral
• Common indication: ADHD
• Available strengths: 30mg, 50mg and 70mg
• Prescription status: Prescription/controlled stimulant medicine
• Typical administration: Once daily, usually in the morning, as prescribed by a doctor.

Benefits

When appropriately prescribed for ADHD, Vyas can help reduce symptoms of inattention, hyperactivity, and impulsive behavior. By increasing the activity of certain neurotransmitters, particularly dopamine and norepinephrine, lisdexamfetamine can support improved attention and behavioral control.

Lisdexamfetamine is also an approved treatment for moderate-to-severe binge-eating disorder in adults in jurisdictions where that indication is authorized. It is not approved simply as a weight-loss medicine.

The 70mg strength is a relatively high dose and should only be used when specifically prescribed. The appropriate dose varies according to the patient's diagnosis, response, age, other medicines, and medical history.

How to Use

• Take Vyas exactly as prescribed.
• It is generally taken once daily in the morning.
• The capsule may usually be taken with or without food.
• Swallow the capsule with water; do not alter the dose yourself.
• Avoid taking it late in the day because it may interfere with sleep.
• Never share the medicine with another person.
• If a dose is missed, follow your prescriber's instructions rather than taking an extra dose.

Zytux 500mg/50mL is a prescription biologic medicine containing rituximab, a monoclonal antibody that targets the CD20 protein on B lymphocytes. By binding to CD20, rituximab causes depletion of certain B cells and helps control diseases in which abnormal B cells contribute to cancer or autoimmune inflammation. Zytux is supplied as a concentrate for intravenous (IV) infusion. Pakistani regulatory information lists Zytux 50mL as containing 500mg of rituximab.

Specifications

• Brand: Zytux
• Active ingredient: Rituximab
• Strength: 500mg/50mL
• Concentration: 10mg/mL
• Dosage form: Concentrate for solution for infusion
• Route: Intravenous infusion
• Pack: Single 50mL vial
• Drug class: Anti-CD20 monoclonal antibody
• Category: Prescription biologic medicine
• Manufacturer: CCL Pharmaceuticals is listed for Zytux in Pakistan's DRAP price database.

Medical Uses

Depending on the approved indication and treatment protocol, rituximab may be prescribed for conditions including:

• Non-Hodgkin's lymphoma, particularly certain CD20-positive B-cell lymphomas
• Chronic lymphocytic leukemia (CLL)
• Rheumatoid arthritis in selected patients
• Granulomatosis with polyangiitis (GPA)
• Microscopic polyangiitis (MPA)
• Certain other CD20-positive blood cancers or autoimmune diseases under specialist care

The exact approved indications vary by country and product labeling.

Benefits

Rituximab works by specifically targeting CD20-positive B cells. In appropriately selected patients with B-cell cancers, reducing these abnormal cells can help control cancer growth and disease activity. In certain autoimmune disorders, B-cell depletion can reduce the abnormal immune activity responsible for inflammation and tissue damage.

For patients with eligible lymphoma or other CD20-positive malignancies, rituximab may be used alone or in combination with chemotherapy or other medicines. In selected autoimmune diseases, it can help reduce disease activity and maintain control when conventional treatments are inadequate or unsuitable.

How to Use

Zytux must not be self-injected. It is administered as a carefully prepared intravenous infusion by trained healthcare professionals in a hospital or specialist infusion setting.

• The prescribed dose depends on the disease, body size, treatment regimen, and clinical response.
• The vial is diluted according to the manufacturer's instructions before infusion.
• Patients are generally monitored closely during and after administration.
• Premedication may be given before infusion to reduce infusion-related reactions.
• The infusion rate is increased gradually according to the approved protocol and patient tolerance.
• The vial should be stored under the manufacturer's specified refrigerated conditions and protected from direct light; the reference rituximab labeling specifies 2–8°C and no freezing or shaking.

Hydrocortisone 10mg is a prescription corticosteroid containing hydrocortisone, a synthetic form of the hormone cortisol naturally produced by the adrenal glands. It has anti-inflammatory and immunosuppressive effects and can also replace cortisol when the body does not produce enough of this hormone. Hydrocortisone tablets are therefore used both for hormone replacement and for selected inflammatory or immune-related conditions.

Specifications

• Active ingredient: Hydrocortisone
• Strength: 10mg per tablet
• Dosage form: Tablet
• Route: Oral
• Drug class: Corticosteroid / glucocorticoid
• Main actions: Cortisol replacement, anti-inflammatory and immunosuppressive effects
• Prescription status: Prescription medicine
• Common uses: Adrenal insufficiency and selected inflammatory conditions
• Administration: Dose and timing depend on the condition and doctor's prescription

Benefits

Hydrocortisone can replace the cortisol that the body normally produces when the adrenal glands are unable to make enough of it. This can help maintain normal blood pressure, energy, metabolism, and the body's response to physical stress in people with adrenal insufficiency.

When used for inflammatory conditions, hydrocortisone reduces inflammatory and immune activity. This can help decrease symptoms such as swelling, redness, pain, and excessive immune-system activity when corticosteroid treatment is medically appropriate.

The medicine can be particularly important for people with adrenal insufficiency because adequate corticosteroid replacement helps prevent potentially serious complications from cortisol deficiency. During significant illness, injury, or surgery, some patients may require a temporary adjustment in their prescribed steroid regimen under medical supervision.

How to Use

• Take hydrocortisone exactly as prescribed by your doctor.
• It is commonly taken with or after food to reduce stomach irritation.
• If prescribed more than once daily, follow the specific timing provided by your healthcare professional.
• Take each dose with water and try to take it at consistent times.
• If you forget a dose, follow your doctor's or pharmacist's instructions rather than taking extra tablets automatically.
• Do not stop long-term hydrocortisone suddenly. The body may have reduced its own cortisol production, and abrupt withdrawal can cause adrenal insufficiency.
• If you are taking hydrocortisone for adrenal insufficiency, ask your doctor about sick-day rules because the dose may need adjustment during fever, infection, surgery, or significant physical stress.

IG VENA 50 g/L is a human normal immunoglobulin (IVIG) medicine supplied as a solution for intravenous infusion. Each 100 mL contains 5 g of human normal immunoglobulin, equivalent to a concentration of 50 g/L. It contains predominantly immunoglobulin G (IgG) antibodies collected from human plasma. The medicine provides antibodies that can either replace missing antibodies in people with certain immune deficiencies or help regulate an abnormal immune response in selected autoimmune and inflammatory conditions.

IG VENA is a prescription hospital medicine and must be administered intravenously under appropriate medical supervision. The exact indications and dosing depend on the patient's diagnosis, age, weight, immune status, and local product authorization.

Specifications

• Brand: IG VENA
• Active substance: Human normal immunoglobulin
• Concentration: 50 g/L (5%)
• Amount: 5 g in 100 mL
• Dosage form: Solution for infusion
• Route: Intravenous infusion
• Drug class: Human immunoglobulin / IVIG
• Main component: Immunoglobulin G (IgG)
• Source: Human plasma
• Administration: Intravenous infusion by trained healthcare professionals
• Storage: Follow the manufacturer's approved storage conditions and protect the product from inappropriate temperature exposure.

Medical Uses

IG VENA may be prescribed for antibody replacement therapy in patients who have insufficient antibody production, including certain primary or secondary immunodeficiency disorders.

IVIG can also be used as immunomodulatory treatment for selected autoimmune or inflammatory conditions. Depending on the approved product indication, examples may include:

• Primary immunodeficiency disorders
• Secondary antibody deficiency
• Immune thrombocytopenia (ITP)
• Guillain–Barré syndrome
• Kawasaki disease
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Certain other immune-mediated disorders when specifically indicated

The approved indications can differ between countries and specific IG VENA product labeling, so treatment should follow the local prescribing information.

Benefits

IG VENA supplies concentrated IgG antibodies directly into the bloodstream. In people who cannot produce enough effective antibodies, this can provide passive immune protection and help reduce the frequency or severity of certain infections.

At immunomodulatory doses, IVIG can influence several components of the immune system. In appropriately selected patients, this may help reduce abnormal inflammation, control immune-mediated disease activity, and improve symptoms or functional outcomes. For example, IVIG is an established treatment option for certain cases of ITP, Kawasaki disease, Guillain–Barré syndrome, and CIDP.

The 5% solution provides a standardized concentration of immunoglobulin, allowing healthcare professionals to calculate the required dose according to the patient's weight and clinical condition.

Polymyxin B for Injection 500,000 IU is a prescription antibiotic containing polymyxin B sulfate. It belongs to the polymyxin group of antibacterial medicines and is supplied as a sterile, lyophilized powder that must be prepared before administration. Polymyxin B is primarily active against susceptible Gram-negative bacteria, including certain strains of Pseudomonas aeruginosa.

Because polymyxin B can cause significant kidney and nervous-system toxicity, it is generally reserved for serious infections when susceptible bacteria are involved and less-toxic alternatives are ineffective or unsuitable.

Specifications

• Product: Polymyxin B for Injection
• Active ingredient: Polymyxin B sulfate
• Strength: 500,000 IU per vial
• Dosage form: Sterile lyophilized powder
• Drug class: Polypeptide antibiotic
• Routes: Intravenous, intramuscular, intrathecal, or ophthalmic, depending on the indication and formulation
• Prescription status: Prescription medicine
• Main antibacterial activity: Susceptible Gram-negative organisms
• Storage before reconstitution: Generally 20–25°C and protected from light; follow the specific product label.

Medical Uses

Polymyxin B may be used for serious infections caused by susceptible bacteria, including certain infections caused by Pseudomonas aeruginosa. Official labeling describes uses that can include:

• Serious urinary-tract infections
• Certain bloodstream infections
• Certain infections involving the meninges
• Certain susceptible eye infections
• Serious infections caused by organisms such as susceptible E. coli, Klebsiella pneumoniae, and Haemophilus influenzae when less-toxic medicines are ineffective or contraindicated.

For meningitis, the labeled route is intrathecal administration, and administration must be performed under specialist medical supervision.

Benefits

When the infecting organism is susceptible, polymyxin B can provide an important treatment option for serious Gram-negative bacterial infections, particularly when other antibiotics cannot be used effectively. Its antibacterial action damages the bacterial cell membrane, resulting in bacterial death.

Its activity against certain multidrug-resistant Gram-negative organisms makes polymyxin B an important hospital antibiotic in selected situations. However, it is not appropriate for routine treatment of ordinary infections and should be selected based on microbiological susceptibility and specialist assessment.

Safacto AF 500 IU is a recombinant human coagulation Factor VIII replacement medicine manufactured by Saman Darou 8. It is supplied as a lyophilized powder for preparation of an injectable solution. The product is used to replace deficient Factor VIII in people with Hemophilia A, helping restore the blood-clotting process and control or prevent bleeding.

Specifications

• Brand: Safacto AF
• Active ingredient: Recombinant coagulation Factor VIII
• Strength: 500 IU per vial
• Dosage form: Lyophilized powder for injection
• Route: Intravenous
• Manufacturer: Saman Darou 8
• Country of manufacture: Iran
• Pack: 4 mL vial with 4 mL solvent, according to a current regulatory listing
• Drug class: Coagulation factor replacement
• Main indication: Factor VIII deficiency / Hemophilia A

Medical Uses

Safacto AF is used under specialist supervision for patients with Hemophilia A, a bleeding disorder caused by insufficient or absent Factor VIII. It may be prescribed for:

• Treatment of acute bleeding episodes
• Prevention of bleeding through prophylactic therapy
• Management of bleeding associated with injuries
• Control of bleeding around surgical or dental procedures
• Replacement of Factor VIII when blood-clotting activity is inadequate

The exact dose depends on factors including the patient's body weight, Factor VIII level, severity and location of bleeding, and clinical response.

Benefits

Safacto AF provides recombinant Factor VIII, replacing the clotting factor that is deficient in Hemophilia A. By increasing Factor VIII activity in the bloodstream, it helps the body's coagulation system form stable blood clots more effectively. This can help control active bleeding and reduce the risk of bleeding episodes when used as prescribed.

For patients receiving preventive therapy, regular Factor VIII replacement can help reduce bleeding frequency and may help protect joints and other tissues from repeated bleeding. It can also provide clotting-factor support during appropriately planned surgical procedures

Safacto AF 500 IU is a recombinant human coagulation Factor VIII replacement medicine manufactured by Saman Darou 8. It is supplied as a lyophilized powder for preparation of an injectable solution. The product is used to replace deficient Factor VIII in people with Hemophilia A, helping restore the blood-clotting process and control or prevent bleeding.

Specifications

• Brand: Safacto AF
• Active ingredient: Recombinant coagulation Factor VIII
• Strength: 500 IU per vial
• Dosage form: Lyophilized powder for injection
• Route: Intravenous
• Manufacturer: Saman Darou 8
• Country of manufacture: Iran
• Pack: 4 mL vial with 4 mL solvent, according to a current regulatory listing
• Drug class: Coagulation factor replacement
• Main indication: Factor VIII deficiency / Hemophilia A

Medical Uses

Safacto AF is used under specialist supervision for patients with Hemophilia A, a bleeding disorder caused by insufficient or absent Factor VIII. It may be prescribed for:

• Treatment of acute bleeding episodes
• Prevention of bleeding through prophylactic therapy
• Management of bleeding associated with injuries
• Control of bleeding around surgical or dental procedures
• Replacement of Factor VIII when blood-clotting activity is inadequate

The exact dose depends on factors including the patient's body weight, Factor VIII level, severity and location of bleeding, and clinical response.

Benefits

Safacto AF provides recombinant Factor VIII, replacing the clotting factor that is deficient in Hemophilia A. By increasing Factor VIII activity in the bloodstream, it helps the body's coagulation system form stable blood clots more effectively. This can help control active bleeding and reduce the risk of bleeding episodes when used as prescribed.

For patients receiving preventive therapy, regular Factor VIII replacement can help reduce bleeding frequency and may help protect joints and other tissues from repeated bleeding. It can also provide clotting-factor support during appropriately planned surgical procedures